Contact
Please use this form to send email to PR contact of this press release:
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
TO:
Please use this form to send email to PR contact of this press release:
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
TO: